Could women with Low-Risk breast cancer safely cut years off their hormone pills?

This large study aims to find out if a shorter course of hormone therapy (2-3 years) works as well as the standard longer treatment for women with a specific, low-risk type of early-stage breast cancer. It will enroll nearly 3,000 patients who will be randomly assigned to receive either the shorter or the standard therapy. The main goal is to see if the shorter treatment is just as good at keeping cancer from coming back over five years, while potentially reducing side effects and improving quality of life.